Mephobarbital

Base Information Edit

Chemical Name:Mephobarbital
CAS No.:115-38-8
Molecular Formula:C13H14N2O3
Molecular Weight:246.266
Hs Code.:2933530000
European Community (EC) Number:204-085-7
UNII:5NC67NU76B
DSSTox Substance ID:DTXSID4023258
Nikkaji Number:J2.468F
Wikipedia:Methylphenobarbital
Wikidata:Q411697
NCI Thesaurus Code:C76528
Metabolomics Workbench ID:43131
ChEMBL ID:CHEMBL45029
Mol file:115-38-8.mol

Synonyms:Mebaral;Mephobarbital;Methylphenobarbital;Methylphenobarbitone;N-Methylphenobarbital;Prominal

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

Chemical Property of Mephobarbital Edit

Chemical Property:

Appearance/Colour:white crystalline solid
Vapor Pressure:5.62E-07mmHg at 25°C
Melting Point:176 °C
Refractive Index:1.543
Boiling Point:395.9 °C at 760 mmHg
PKA:7.99±0.10(Predicted)
Flash Point:193.2 °C
PSA：66.48000
Density:1.212 g/cm³
LogP:1.30930
Storage Temp.:Controlled Substance, -20?C Freezer
Solubility.:Practically insoluble in water, very slightly soluble in ethanol (96 per cent).
Water Solubility.:0.15g/L(20 oC)
XLogP3:1.8
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:2
Exact Mass:246.10044231
Heavy Atom Count:18
Complexity:388

Purity/Quality:

Safty Information:

Pictogram(s): Xn,T,F
Hazard Codes:Xn,T,F
Statements: 22-39/23/24/25-23/24/25-11
Safety Statements: 36/37/39-45-36/37-16-7

MSDS Files:: SDS file from LookChem

Useful:

Canonical SMILES:CCC1(C(=O)NC(=O)N(C1=O)C)C2=CC=CC=C2
Uses Controlled substance (depressant). Anticonvulsant; sedative; hypnotic
Therapeutic Function Anticonvulsant
Clinical Use Mephobarbital is a barbiturate-derivative AED with a pKa of 7.7 (log P = 1.84 at pH 7.4). Approximately 50% of an oral dose of mephobarbital is absorbed from the gastrointestinal tract. The plasma concentrations required for its therapeutic effects are unknown. The principal route of mephobarbital metabolism is N-demethylation by the liver to form phenobarbital, which may be excreted in the urine unchanged and as its p-hydroxy metabolite and glucuronide or sulfate conjugates. Conversion to the 4-hydroxy metabolite is stereoselective, being catalyzed by either CYP2C19 (R-enantiomer) or CYP2B6 (S-enantiomer); individuals who are CYP2C19 poor metabolizers show decreased clearance. Approximately 75% of a single oral dose of mephobarbital is converted to phenobarbital. It has not been determined whether mephobarbital contributes to the antiseizure effect or whether it results from its active metabolite, phenobarbital. Similarly, it is unclear whether mephobarbital, like phenobarbital, is a potent inducer of the enzymes involved in the metabolism of other drugs, but because the drug is chemically and pharmacologically similar to phenobarbital and is metabolized to phenobarbital, this possibility is likely. Mephobarbital is less commonly used in the treatment of generalized and partial seizures. Like phenobarbital, it is classified as a long-acting barbiturate. No evidence exists that it is more effective than phenobarbital in equivalent doses; however, it may be less sedating in children.

Technology Process of Mephobarbital

There total 11 articles about Mephobarbital which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 24.0%